Search

Your search keyword '"Wu, Anna M."' showing total 620 results
Start Over "Wu, Anna M."

Refine your results

more »

more »

more »

more »
620 results on '"Wu, Anna M."'

153. Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors.

Author

Postow, Michael A., primary, Harding, James J., additional, Hellmann, Matthew David, additional, Gordon, Michael S., additional, Tsai, Frank, additional, O' Donoghue, Joseph A., additional, Lewis, Jason Stuart, additional, Wu, Anna M, additional, Le, William, additional, Korn, Ronald Lee, additional, Weber, Wolfgang, additional, Wolchok, Jedd D., additional, and Pandit-Taskar, Neeta, additional

Published
2018
Full Text
View/download PDF

158. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

Author

Priceman, Saul J., primary, Gerdts, Ethan A., additional, Tilakawardane, Dileshni, additional, Kennewick, Kelly T., additional, Murad, John P., additional, Park, Anthony K., additional, Jeang, Brook, additional, Yamaguchi, Yukiko, additional, Yang, Xin, additional, Urak, Ryan, additional, Weng, Lihong, additional, Chang, Wen-Chung, additional, Wright, Sarah, additional, Pal, Sumanta, additional, Reiter, Robert E., additional, Wu, Anna M., additional, Brown, Christine E., additional, and Forman, Stephen J., additional

Published
2017
Full Text
View/download PDF

160. Identifying CD38+cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

Author

Krishnan, Amrita, Adhikarla, Vikram, Poku, Erasmus K., Palmer, Joycelynne, Chaudhry, Ammar, Biglang-awa, Van Eric, Bowles, Nicole, Nathwani, Nitya, Rosenzweig, Michael, Sahebi, Firoozeh, Karanes, Chatchada, Simpson, Jennifer, Sanchez, James F., Yamauchi, Dave, Parayno, Maria, Chowdhury, Arnab, Caserta, Enrico, Marcucci, Guido, Rockne, Russell, Wu, Anna M., Wong, Jeffrey, Forman, Stephen J., Colcher, David, Yazaki, Paul, Shively, John, and Pichiorri, Flavia

Abstract

18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM). Intracellular FDG uptake depicts in vivo metabolic activity, which can be seen in both malignant and nonmalignant cells, resulting in limited sensitivity and specificity. Our group showed preclinically that tracing MM dissemination using a CD38-directed human antibody, daratumumab, that is radioconjugated with 64Cu via the chelator DOTA (64Cu-daratumumab), led to improved sensitivity and specificity over that of FDG. Here, we report the results of a phase 1 trial designed to (1) assess the safety and feasibility of 64Cu-daratumumab PET/CT and (2) preliminarily evaluate and characterize the ability of 64Cu-daratumumab to accurately detect or exclude MM lesions. A total of 12 daratumumab-naive patients were imaged. Prior to the injection of 15 mCi/5 mg of 64Cu-daratumumab, patients were treated with 0 (n = 3), 10 (n = 3), 45 (n = 3), or 95 mg (n = 3) of unlabeled daratumumab to assess its effect on image quality. No significant adverse events were observed from either unlabeled daratumumab or 64Cu-daratumumab. Of the dose levels tested, 45 mg unlabeled daratumumab was the most optimal in terms of removing background signal without saturating target sites. 64Cu-daratumumab PET/CT provided safe whole-body imaging of MM. A trial comparing the sensitivity and specificity of 64Cu-daratumumab PET/CT with that of FDG PET/CT is planned. This trial was registered at www.clinicaltrials.govas #NCT03311828.

Published
2020
Full Text
View/download PDF

161. Immune Modulation Therapy and Imaging: Workshop Report

Author

Shields, Anthony F., primary, Jacobs, Paula M., additional, Sznol, Mario, additional, Graham, Michael M., additional, Germain, Ron N., additional, Lum, Lawrence G., additional, Jaffee, Elizabeth M., additional, de Vries, Elisabeth G.E., additional, Nimmagadda, Sridhar, additional, Van den Abbeele, Annick D., additional, Leung, David K., additional, Wu, Anna M., additional, Sharon, Elad, additional, and Shankar, Lalitha K., additional

Published
2017
Full Text
View/download PDF

166. Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation

Author

Tavaré, Richard, Wu, Wei H, Zettlitz, Kirstin A, Salazar, Felix B, McCabe, Katelyn E, Marks, James D, and Wu, Anna M

Subjects
Technology, Biophysics, Cell Line, Heterocyclic Compounds, Activated-Leukocyte Cell Adhesion Molecule, Animals, Humans, Tissue Distribution, ALCAM, Cancer, 1-Ring, Tumor, Cu-64, site-specific conjugation, Biological Sciences, Immunohistochemistry, Rats, Molecular Imaging, Colo-Rectal Cancer, DOTA, Positron-Emission Tomography, Chemical Sciences, Colorectal Neoplasms, immunoPET, Digestive Diseases, Copper
Abstract

Activated leukocyte cell adhesion molecule (ALCAM) is an immunoglobulin superfamily cell adhesion molecule that is aberrantly expressed in a wide variety of human tumors, including melanoma, prostate cancer, breast cancer, colorectal carcinoma, bladder cancer and pancreatic adenocarcinoma. This wide spectrum of human malignancies makes ALCAM a prospective pan-cancer immunoPET target to aid in detection and diagnosis in multiple malignancies. In this study, we assess site-specific versus non-site-specific conjugation strategies for (64)Cu-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) immunoPET imaging of a fully human ALCAM cys-diabody (cDb) with a reduced linker length that retains its bivalent binding ability. ALCAM constructs with linker lengths of eight, five and three amino acids were produced to make true non-covalent site-specifically modified cDbs. Characterization by gel electrophoresis, size exclusion chromatography, flow cytometry and mass spectrometry of the various constructs was performed. To demonstrate the increased utility of targeting multiple malignancies expressing ALCAM, we compare the targeting of the site-specific versus non-site-specific conjugated cDbs to the human colorectal cancer xenograft LS174T. Interestingly, the conjugation strategy not only affects tumor targeting but also hepatic and renal uptake/clearance.

Published
2014

168. 18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

Author

Tsai, Wen-Ting K., Collins, Jeffrey, Zettlitz, Kirstin A., Wu, Anna M., Tavaré, Richard, Ha, Noel S., van Dam, R. Michael, Yamada, Reiko E., and Timmerman, John M.

Subjects
LYMPHOMAS, CD20 antigen, IMMUNOGLOBULINS, POSITRON emission, FLUORODEOXYGLUCOSE F18, GENE expression, DIAGNOSTIC imaging
Abstract

Purpose: Metabolic imaging using [18F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (18F, t1/2 110 min), enabling same-day imaging.Methods: GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[18F]-fluorobenzoate ([18F]SFB), or thiol-reactive N-[2-(4-[18F]-fluorobenzamido)ethyl]maleimide ([18F]FBEM) for site-specific conjugation to C-terminal cysteine residues. Both tracers were used for immunoPET imaging of the B cell compartment in human CD20 transgenic mice (hCD20TM). [18F]FB-GAcDb immunoPET was further evaluated in a disseminated lymphoma (A20-hCD20) syngeneic for hCD20TM and compared to [18F]FDG PET. Tracer uptake was confirmed by ex vivo biodistribution.Results: The GAcDb was successfully 18F-radiolabeled using two different conjugation methods resulting in similar specific activities and without impairing immunoreactivity. Both tracers ([18F]FB-GAcDb and [18F]FBEM-GAcDb) specifically target human CD20-expressing B cells in transgenic mice. Fast blood clearance results in high contrast PET images as early as 1 h post injection enabling same-day imaging. [18F]FB-GAcDb immunoPET detects disseminated lymphoma disease in the context of normal tissue expression of hCD20, with comparable sensitivity as [18F]FDG PET but with added specificity for the therapeutic target.Conclusions: [18F]FB-GAcDb and [18F]FBEM-GAcDb could monitor normal B cells and B cell malignancies non-invasively and quantitatively in vivo. In contrast to [18F]FDG PET, immunoPET provides not only information about the extent of disease but also about presence and localisation of the therapeutic target. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

169. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake

Author

Pandit-Taskar, Neeta, primary, O’Donoghue, Joseph A., additional, Ruan, Shutian, additional, Lyashchenko, Serge K., additional, Carrasquillo, Jorge A., additional, Heller, Glenn, additional, Martinez, Danny F., additional, Cheal, Sarah M., additional, Lewis, Jason S., additional, Fleisher, Martin, additional, Keppler, Jennifer S., additional, Reiter, Robert E., additional, Wu, Anna M., additional, Weber, Wolfgang A., additional, Scher, Howard I., additional, Larson, Steven M., additional, and Morris, Michael J., additional

Published
2016
Full Text
View/download PDF

170. Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time

Author

Sonn, Geoffrey A., primary, Behesnilian, Andrew S., additional, Jiang, Ziyue Karen, additional, Zettlitz, Kirstin A., additional, Lepin, Eric J., additional, Bentolila, Laurent A., additional, Knowles, Scott M., additional, Lawrence, Daniel, additional, Wu, Anna M., additional, and Reiter, Robert E., additional

Published
2016
Full Text
View/download PDF

171. A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa).

Author

Morris, Michael J., primary, Martinez, Danny Francisco, additional, Durack, Jeremy C., additional, Slovin, Susan F., additional, Danila, Daniel Costin, additional, O' Donoghue, Joseph A., additional, Parada, Nicole Andrea, additional, Lyashchenko, Serge K., additional, Carrasquillo, Jorge A., additional, Ruan, Shutian, additional, Lewis, Jason Stuart, additional, Keppler, Jennifer, additional, Wu, Anna M., additional, Reuter, Victor E., additional, Weber, Wolfgang, additional, Scher, Howard I., additional, Larson, Steven M., additional, and Pandit-Taskar, Neeta, additional

Published
2016
Full Text
View/download PDF

172. Dual transcript and protein quantification in a massive single cell array

Author

Park, Seung-min, primary, Lee, Jae Young, additional, Hong, Soongweon, additional, Lee, Sang Hun, additional, Dimov, Ivan K., additional, Lee, Hojae, additional, Suh, Susie, additional, Pan, Qiong, additional, Li, Keyu, additional, Wu, Anna M., additional, Mumenthaler, Shannon M., additional, Mallick, Parag, additional, and Lee, Luke P., additional

Published
2016
Full Text
View/download PDF

175. Immune Modulation Therapy and Imaging: Workshop Report.

Author

Shields, Anthony F., Jacobs, Paula M., Sznol, Mario, Graham, Michael M., Germain, Ron N., Lum, Lawrence G., Jaffee, Elizabeth M., de Vries, Elisabeth G. E., Nimmagadda, Sridhar, Van den Abbeele, Annick D., Leung, David K., Wu, Anna M., Sharon, Elad, and Shankar, Lalitha K.

Published
2018
Full Text
View/download PDF

176. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.

Author

Jianqin Lu, Xiangsheng Liu, Yu-Pei Liao, Salazar, Felix, Bingbing Sun, Wen Jiang, Chong Hyun Chang, Jinhong Jiang, Xiang Wang, Wu, Anna M., Huan Meng, and Nel, Andre E.

Abstract

While chemotherapy delivery by nanocarriers has modestly improved the survival prospects of pancreatic ductal adenocarcinoma (PDAC), additional engagement of the immune response could be game changing. We demonstrate a nano-enabled approach for accomplishing robust anti-PDAC immunity in syngeneic mice through the induction of immunogenic cell death (ICD) as well as interfering in the immunosuppressive indoleamine 2,3-dioxygenase (IDO) pathway. This is accomplished by conjugating the IDO inhibitor, indoximod (IND), to a phospholipid that allows prodrug self-assembly into nanovesicles or incorporation into a lipid bilayer that encapsulates mesoporous silica nanoparticles (MSNP). The porous MSNP interior allows contemporaneous delivery of the ICD-inducing chemotherapeutic agent, oxaliplatin (OX). The nanovesicles plus free OX or OX/IND-MSNP induce effective innate and adaptive anti-PDAC immunity when used in a vaccination approach, direct tumor injection or intravenous biodistribution to an orthotopic PDAC site. Significant tumor reduction or eradication is accomplishable by recruiting cytotoxic T lymphocytes, concomitant with downregulation of Foxp3+ T cells. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

182. Abstract 4300: Receptor occupancy and tumor penetration by antibodies, peptides, and antibody fragments: Molecular simulation of imaging assessment

Author

Orcutt, Kelly D., primary, Adams, Gregory P., additional, Wu, Anna M., additional, Silva, Matthew, additional, Hoppin, Jack, additional, Harwell, Catey, additional, Matsumura, Manabu, additional, Kotsuma, Masakatsu, additional, Freeman, Daniel, additional, Tse, Archie, additional, Greenberg, Jonathan, additional, Scott, Andrew, additional, and Beckman, Robert A., additional

Published
2014
Full Text
View/download PDF

184. Recombinant anti-CD20 antibody fragments for microPET imaging of B-cell lymphoma

Author

Olafsen, Tove, Betting, David, Kenanova, Vania E., Salazar, Felix B., Clarke, Pat, Said, Jonathan, Raubitschek, Andrew A., Timmerman, John M., and Wu, Anna M.

Subjects
Mice, Inbred C3H, Lymphoma, B-Cell, Antibodies, Monoclonal, Reproducibility of Results, Sensitivity and Specificity, Article, Antibodies, Monoclonal, Murine-Derived, Disease Models, Animal, Mice, immune system diseases, hemic and lymphatic diseases, Positron-Emission Tomography, Animals, Humans, Female, Radiopharmaceuticals, Rituximab, Immunoglobulin Fragments
Abstract

The CD20 cell surface antigen is expressed at high levels by over 90% of B-cell non-Hodgkin lymphomas (NHL) and is the target of the anti-CD20 monoclonal antibody rituximab. To provide more sensitive, tumor-specific PET imaging of NHL, we sought to develop PET agents targeting CD20.Two recombinant anti-CD20 rituximab fragments, a minibody (scFv-C(H)3 dimer; 80 kDa) and a modified scFv-Fc fragment (105 kDa), designed to clear rapidly, were generated. Both fragments were radiolabeled with (124)I, and the minibody was additionally labeled with (64)Cu (radiometal) after conjugation to 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). The radioiodinated fragments and the radiometal-labeled minibody were evaluated in mice as small-animal PET imaging agents for the in vivo imaging of human CD20-expressing lymphomas.Rapid and specific localization to CD20-positive tumors was observed with the radioiodinated fragments. However, the tumor uptake levels and blood activities differed, resulting in different levels of contrast in the images. The better candidate was the minibody, with superior uptake (2-fold higher than that obtained with scFv-Fc) in CD20-positive tumors and low uptake in CD20-negative tumors. Ratios of CD20-positive tumors to CD20-negative tumors at 21 h were 7.0 +/- 3.1 (mean +/- SD) and 3.9 +/- 0.7 for the minibody and scFv-Fc, respectively. The ratio achieved with the (64)Cu-DOTA-minibody at 19 h was about 5-fold lower because of higher residual background activity in CD20-negative tumors.A radioiodinated minibody and a radioiodinated scFv-Fc fragment produced excellent, high-contrast images in vivo. These new immunoPET agents may prove useful for imaging CD20-positive lymphomas in preclinical models and in humans with NHL.

Published
2009

186. ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging.

Author

Freise, Amanda, Zettlitz, Kirstin, Salazar, Felix, Lu, Xiang, Tavaré, Richard, Wu, Anna, Freise, Amanda C, Zettlitz, Kirstin A, Salazar, Felix B, Tavaré, Richard, and Wu, Anna M

Subjects
POSITRON emission tomography, CELL imaging, T cells, CD4 antigen, MOLECULAR probes, CANCER immunotherapy
Abstract

Purpose: Molecular imaging of CD4+ T cells throughout the body has implications for monitoring autoimmune disease and immunotherapy of cancer. Given the key role of these cells in regulating immunity, it is important to develop a biologically inert probe. GK1.5 cys-diabody (cDb), a previously developed anti-mouse CD4 antibody fragment, was tested at different doses to assess its effects on positron emission tomography (PET) imaging and CD4+ T cell viability, proliferation, CD4 expression, and function.Procedures: The effect of protein dose on image contrast (lymphoid tissue-to-muscle ratio) was assessed by administering different amounts of 89Zr-labeled GK1.5 cDb to mice followed by PET imaging and ex vivo biodistribution analysis. To assess impact of GK1.5 cDb on T cell biology, GK1.5 cDb was incubated with T cells in vitro or administered intravenously to C57BL/6 mice at multiple protein doses. CD4 expression and T cell proliferation were analyzed with flow cytometry and cytokines were assayed.Results: For immunoPET imaging, the lowest protein dose of 2 μg of 89Zr-labeled GK1.5 cDb resulted in significantly higher % injected dose/g in inguinal lymph nodes (ILN) and spleen compared to the 12-μg protein dose. In vivo administration of GK1.5 cDb at the high dose of 40 μg caused a transient decrease in CD4 expression in spleen, blood, lymph nodes, and thymus, which recovered within 3 days postinjection; this effect was reduced, although not abrogated, when 2 μg was administered. Proliferation was inhibited in vivo in ILN but not the spleen by injection of 40 μg GK1.5 cDb. Concentrations of GK1.5 cDb in excess of 25 nM significantly inhibited CD4+ T cell proliferation and interferon-γ production in vitro. Overall, using low-dose GK1.5 cDb minimized biological effects on CD4+ T cells.Conclusions: Low-dose GK1.5 cDb yields high-contrast immunoPET images with minimal effects on T cell biology in vitro and in vivo and may be a useful tool for investigating CD4+ T cells in the context of preclinical disease models. Future approaches to minimizing biological effects may include the creation of monovalent fragments or selecting anti-CD4 antibodies which target alternative epitopes. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

187. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Author

Pandit-Taskar, Neeta, O'Donoghue, Joseph A., Ruan, Shutian, Lyashchenko, Serge K., Carrasquillo, Jorge A., Heller, Glenn, Martinez, Danny F., Cheal, Sarah M., Lewis, Jason S., Fleisher, Martin, Keppler, Jennifer S., Reiter, Robert E., Wu, Anna M., Weber, Wolfgang A., Scher, Howard I., Larson, Steven M., and Morris, Michael J.

Published
2016
Full Text
View/download PDF

198. Levels of Murine, but Not Human, CXCL13 Are Greatly Elevated in NOD-SCID Mice Bearing the AIDS-Associated Burkitt Lymphoma Cell Line, 2F7

Author

Widney, Daniel P., primary, Olafsen, Tove, additional, Wu, Anna M., additional, Kitchen, Christina M. R., additional, Said, Jonathan W., additional, Smith, Jeffrey B., additional, Peña, Guadalupe, additional, Magpantay, Larry I., additional, Penichet, Manuel L., additional, and Martinez-Maza, Otoniel, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results